Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Ocrelizumab is a humanized anti-CD20 monoclonal antibody that showed in phase III trials a
powerful effect on relapse rate and lesion load accumulation in the relapsing form of
multiple sclerosis (RMS). This therapeutic agent also showed for the first time a significant
reduction of disability progression in Primary Progressive Multiple Sclerosis (PPMS)
patients, whereas all other anti-inflammatory drugs had failed to do so in well-conducted
studies. This raises the possibility that ocrelizumab, beyond its effects on the adaptive
immune system activation underlying white matter lesions and clinical relapses, could
beneficially influence other mechanisms involved in the progressive phase of the disease,
such as the innate immune microglial cells activation, that has been described to persist in
a diffuse manner in the Central Nervous system (CNS). To date the activation of these cells
is not accessible to classical Magnetic Resonance Imaging (MRI) techniques, impeding the full
investigation of the therapeutic efficacy of drugs such as ocrelizumab.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Institut du Cerveau et de la Moelle épinière Roche Pharma AG